FDA granted RMAT Designation and EMA granted Orphan Designation for CAN-2409, a drug candidate from Candel Therapeutics.
2 reports, 1 independent
Updated Aug 14
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted RMAT Designation and EMA granted Orphan Designation for CAN-2409, a drug candidate from Candel Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Candel Therapeutics
company in Auburndale, United States
Nothing else this week.
Related events
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Ensysce is listed on NASDAQ and received FDA Orphan Drug Designation for its CRPS therapy.
- The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.
Coverage
Newest first; wire copies grouped- GlobeNewswireCandel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409
- GlobeNewswireCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Comp